French precision fermentation startup Standing Ovation has raised EUR 3.75 million (~USD 4.2 million) in a Series A extension round, bringing its total Series A funding to EUR 15.75 million (~USD 17.5 million).
The funding will be used to scale up production of Advanced Casein, the company's first patented product, ahead of a planned market launch in the US in 2025. Standing Ovation aims to finalize preparations for industrial-scale production by the end of 2024.
In addition to the funding, the company announced the appointment of Yves Chardonnens as CEO. Chardonnens has previously held C-suite positions at Oterra, Firmenich, IFF, Unilever, Barry Callebaut, and Roquette.
Analyst QuickTake: Including Series A funding and a EUR 3 million (~USD 3.3 million) government grant received earlier this year, Standing Ovation has now raised a total of EUR 23 million (~USD 26 million). Since its product is made through precision fermentation, GRAS status will be required in the US before commercialization; so far, New Culture is the only precision fermentation company to have achieved this milestone.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.